Stockwinners Market Radar for October 02, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT Supermicro, Fujitsu enter strategic collaboration on AI computing technology - Fujitsu Limited (FJTSY) and Supermicro (SMCI) "announced they will collaborate to establish a long-term strategic engagement in technology and business, to develop and market a platform with Fujitsu's future Arm-based "FUJITSU-MONAKA" processor that is designed for high-performance and energy efficiency and targeted for release in 2027. In addition, the two companies will also collaborate on developing liquid-cooled systems for HPC, Gen AI, and next-generation green data centers. In addition, by integrating Fujitsu's cutting-edge "FUJITSU-MONAKA" processor, the two companies will realize excellent performance and power efficiency while also pursuing high reliability, security, and ease of use with wide software compatibility, thereby empowering customers to implement green AI infrastructure. FUJITSU-MONAKA is a processor based on the Arm instruction set architecture, employing cutting-edge 2-nanometer technology and is set to be delivered in 2027. This new technology applied to the FUJITSU-MONAKA is based on results obtained from a project subsidized by the New Energy and Industrial Technology Development Organization."

19:50 EDT Cemtrex trading halted, news pending

19:12 EDT Farmland Partners to sell $289M of farmland to Farmland Reserve - Farmland Partners "announced that it is selling a portfolio of 46 farms, comprising 41,554 acres of farmland, for $289M in a single transaction with Farmland Reserve, Inc. The all-cash deal has been finalized by both parties and is scheduled to close on October 16, 2024, once all conditions to closing are satisfied. The Portfolio includes farms across several regions and states, including Arkansas, Florida, Louisiana, Mississippi, Nebraska, Oklahoma, and the Carolinas. The Transaction does not include any of the Company's Illinois farmland, which is among the most valuable land it owns. FPI's total gain on sale will be approximately $50M, or approximately 21% over the aggregate net book value of the farms comprising the Portfolio. In 2023, FPI also sold approximately $200M of assets at a gain in excess of 20%."

19:04 EDT GAP Airports reports September traffic down 3.6% - The company states: "For September 2024, the total number of terminal passengers at GAP's 12 Mexican airports decreased by 3.6%, compared to September 2023. Guadalajara airport presented an increase in passenger traffic of 4.1%, while Los Cabos, Tijuana, and Puerto Vallarta airports presented a decrease in passenger traffic of 9.9%, 6.2%, and 5.1% respectively, compared to September 2023. On the other hand, Montego Bay presented a decrease in passenger traffic of 11.5%."

18:04 EDT Monogram Orthopaedics receives FDA response for mBos TKA system - Monogram Technologies "announced that it has received an Additional Information Request from the U.S. Food and Drug Administration on September 30, 2024, regarding its 510(k) premarket filing submission for the Company's mBos TKA System. The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. The FDA informed the Company that the FDA placed the Application on hold pending a complete response to the AIR. The FDA has informed the Company that the Company has 180 days from the date of the AIR to provide a complete response to the AIR or the FDA will consider the Application withdrawn."

17:49 EDT Samsara CEO sells $4.5M in common stock - In a regulatory filing, Samsara disclosed that its CEO Sanjit Biswas sold 96K shares of common stock on October 1st in a total transaction size of $4.5M.

17:20 EDT Chipotle announces opening of first restaurant in Dubai - Chipotle Mexican Grill announces the opening of its first restaurant in Dubai in partnership with leading international franchise retail operator Alshaya Group. Located at 'The Beach' at Jumeirah Beach Residence, this new location marks Chipotle's first restaurant in the United Arab Emirates, with a second location planned to open in the region at the Dubai Hills Mall in the coming months. The new Chipotle at JBR is set in a marquee location along the beachside boulevard, spanning over 6,000 square feet, and is open from 10:00am - 12:00am local time on weekdays; and until 1:00am local time on weekends.In April, Chipotle's expansion into the Middle East began with a restaurant at The Avenues, Kuwait's largest shopping mall, which marked the first time the company had entered a new country in over 10 years. Last month, Alshaya Group opened a second Chipotle restaurant in Kuwait, located at The Walk Mall in Ardiya. "We are thrilled by the overwhelming response to Chipotle's responsibly sourced, classically-cooked, real ingredients in Kuwait and hope to see similar enthusiasm at our JBR restaurant," said Chief Business Development Officer Nate Lawton. "Alshaya has been a tremendous partner and continues to ensure our culinary and our purpose to cultivate a better world are clear points of differentiation for consumers as we enter these new regions." Reference Link

17:03 EDT Eupraxia Pharmaceuticals names Amanda Malone as Chief Scientific Officer - Eupraxia Pharmaceuticals "announced the recent appointments of Chief Scientific Officer Amanda Malone, as Chief Operating and Scientific Officer, and Rahul Sarugaser, as Executive Vice President of Corporate Development. Dr. Malone co-founded Eupraxia with Dr. Helliwell in 2012 and built Eupraxia's research, manufacturing, quality, non-clinical, regulatory, intellectual property and clinical functions. She is listed as inventor on six patent families that have resulted in more than 70 patents and patent applications. Over the past 20 years, Dr. Sarugaser has held progressively senior roles in the capital markets and healthcare sector, and was most recently Managing Director, Equity Research, Biotech & Medtech with Raymond James, where he actively covered Eupraxia."

16:59 EDT Lockheed Martin announces additional $3B share repurchase authorization - The company's board has also authorized the purchase of up to an additional $3B of Lockheed Martin common stock under its share repurchase program. With this increase, total authorization for future repurchases under the share repurchase program is approximately $10B.

16:57 EDT Lockheed Martin increases quarterly dividend to $3.30 per share - Lockheed Martin board of directors has authorized a fourth quarter 2024 dividend of $3.30 per share. This is an increase of 15c per share over the last quarter and represents the company's 22nd consecutive year of dividend increases. The dividend is payable on December 27 to holders of record as of the close of business on December 2.

16:49 EDT Southwest Director Rakesh Gangwal purchases $21M in company shares - Southwest Airlines Director Rakesh Gangwal disclosed the purchase of 705,904 shares of company stock at $29.65 per share on September 30, for a total transaction amount of $20,928,712.

16:45 EDT Analog Devices exec Bryant sells 30,000 common shares - In a regulatory filing, Analog Devices executive VP Gregory Bryant disclosed the sale of 30,000 common shares of the company on October 1 at a price of $228.93 per share.

16:36 EDT Heritage Commerce names Thomas Sa COO - Heritage Commerce (HBTK) announced the appointment of Thomas Sa as the COO of the company and the bank. As COO, Sa will report directly to CEO Robertson Jones and will have primary responsibility for banking operations, risk management, and information technology systems. Sa had previously served as president, COO and CFO of California BanCorp (BCAL) and its subsidiary, California Bank of Commerce, which merged with Southern California Bancorp in July.

16:33 EDT Spero Therapeutics announces publication of SPR719 trial data - Spero Therapeutics announced the publication of data from its Phase 1 clinical trial, which assessed the intrapulmonary pharmacokinetics, or PK, of SPR719. The full manuscript was published ahead of print in Antimicrobial Agents and Chemotherapy. This was a Phase 1, single-center, open-label study in healthy adult male and female subjects. Subjects received a 1,000 mg dose of SPR720 administered once daily for 7 days. Blood samples were collected for plasma pharmacokinetic assessments. Each subject also underwent a standardized bronchoscopy and Bronchoalveolar Lavage on Day 7. The safety population comprised 33 healthy adult subjects, and the PK population included 30 subjects. There were no meaningful concentrations of SPR720 detected in the plasma. Mean plasma concentrations of SPR719 reached a peak at approximately 4 hours and then declined over the remaining 24 hours. The concentrations of SPR719 in ELF and AM were found to be greater than total plasma concentrations. These results suggested that SPR719 had significant lung uptake and enhanced ELF and AM concentrations because unbound plasma concentrations predominantly influence penetration into lung compartments. No unexpected safety findings were observed. Results from this study of the intrapulmonary disposition of SPR719 support further investigation of SPR720 as a potential oral agent for treatment of NTM-PD.

16:31 EDT Southwest director buys $34.9M in common stock - In a regulatory filing, Southwest disclosed that its director Rakesh Gangwal bought 1.18M shares of common stock on September 30th in a total transaction size of $34.9M. Shares of Southwest are up 2% afterhours at $30.17.

16:25 EDT P10 subsidiary awarded $65M allocation from NMTC program - P10 announced Enhanced Community Development, a part of P10 subsidiary Enhanced Capital Group, was awarded a $65M allocation from the New Markets Tax Credits, or NMTC, program administered by the U.S. Treasury Department's Community Development Financial Institutions Fund. Under the program, the U.S. Treasury Department allocated a total of $5B to 104 Community Development Entities for the 2023 round.

16:23 EDT BigCommerce CEO Brent Bellm to depart, Travis Hess to succeed - BigCommerce (BIGC) announced the appointment of Travis Hess as CEO. Brent Bellm will no longer serve as CEO of the company or as chairman of the board. The board elected Hess as a director of the company, to fill the vacancy created by Bellm's departure. Current board member Ellen Siminoff will assume the role of executive chair of the board, effective immediately. Hess joined BigCommerce as president in May and previously held senior leadership roles at global commerce agencies and consultancies such as Accenture (ACN).

16:15 EDT Globus Maritime takes delivery of 'Glbs Magic' - Globus Maritime announced that it took delivery of the M/V "Glbs Magic," a 2024 new built Ultramax dry bulk carrier, on September 20. The M/V "Glbs Magic" was built at the Nantong Cosco KHI Ship Engineering and has a carrying capacity of approximately 64,000 DWT.

16:14 EDT Fidelity National acquires First Nationwide Title Agency - Fidelity National announced the acquisition of the commercial operations of First Nationwide Title Agency, a division of AMT Commercial Title Services and a subsidiary of AmTrust Financial Services. Founded in 2012 and headquartered in NYC, FNTA closes and insures commercial real estate transactions all over the U.S. As part of the acquisition, FNTA's key commercial leadership team will join FNF. Steven Napolitano, FNTA's President and CEO, will continue to lead the company's day-to-day operations under FNF's ownership.

16:13 EDT Kineta announces TuHURA Biosciences extends exclusivity agreement for KVA12123 - Kineta announced that TuHURA Biosciences is exercising its right to extend their exclusivity and right of first offer agreement for Kineta's Vista blocking antibody KVA12123. Under the terms of the agreement entered in July between Kineta and TuHURA, TuHURA has the right to extend their rights for up to two 10-day periods. Kineta is entitled to receive $150,000 for each 10-day extension. On July 8, Kineta announced that it had entered into the agreement with TuHURA, a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. As part of the agreement, Kineta received a $5M nonrefundable payment from TuHURA in July. Under the terms of the agreement, any payment made by TuHURA in consideration for Kineta's compliance with its obligations set forth in the agreement will be credited to the upfront payment from TuHURA if a transaction between the parties is completed. In August, Kineta announced that in collaboration with TuHURA, it reopened enrollment in the VISTA-101 clinical trial. Kineta and TuHURA continue to collaborate on the ongoing Phase 1 clinical program for patients with advanced solid tumor cancer.

16:11 EDT Parsons awarded position on $4B defense threat reduction agency contract - Parsons announced that the company was awarded a position on an indefinite-delivery, indefinite-quantity IDIQ multiple award task order contract MATOC by the Defense Threat Reduction Agency DTRA to support Countering Weapons Of Mass Destruction CWMD objectives. The $4B ceiling value contract includes a five-year base period and one five-year option period and is new work for the company. Under this contract, Parsons will compete for task orders to perform research, development, testing and evaluation, procurement, maintenance, and systems engineering to deliver scientific and technological solutions meeting the Department of Defense's priority CWMD objectives. "We have strong, proven technical capabilities that enable efforts by the United States and partner nations to counter and deter global threats," said Jon Moretta, President, Engineered Systems for Parsons. "We're proud to leverage these capabilities and our core strengths in global security solutions support and development to advance DTRA's mission to prevent, reduce, and counter WMD and emerging threats in an increasingly complex and dynamic environment."

16:07 EDT Radiant Logistics acquires Focus Logistics - Radiant Logistics has acquired the operations Focus Logistics, a Michigan based, privately held company with operations in Romulus, Michigan that has operated under the company's Service By Air brand since 2006. The company structured the transaction with a portion of the expected purchase price payable in subsequent periods based on the future performance of the acquired operations. Originally founded in 2003 and operated by Terrie Evans and Cliff Kisielewski, Focus provides both domestic and international freight forwarding services in support of the marine, aerospace, brand management and trade show industries. On a post-closing basis, Focus is expected to transition to the Radiant brand and will combine with existing company owned operations in the Detroit area and operate under the leadership of Cliff Kisielewski who will assume the role of General Manager for the newly combined organization.

16:03 EDT Colliers International engineering platform acquires GWAL, terms undisclosed - Colliers announced that its Canadian engineering platform, Englobe Corporation, has acquired Goodkey, Weedmark & Associates Limited, or GWAL, a building engineering consulting firm in Ontario. GWAL's leadership team will become shareholders of Englobe under Colliers' unique partnership model. The business will be fully integrated into Englobe's operations and will rebrand as Colliers in the future. Terms of the transaction were not disclosed. Founded in 1956, GWAL's 100 professionals provide mechanical and electrical engineering consulting services to public and private clients throughout Ontario, with a focus around the National Capital and Ottawa Valley regions.

15:26 EDT OpenAI announces new funding to scale the benefits of AI - "We are making progress on our mission to ensure that artificial general intelligence benefits all of humanity. Every week, over 250 million people around the world use ChatGPT to enhance their work, creativity, and learning. Across industries, businesses are improving productivity and operations, and developers are leveraging our platform to create a new generation of applications. And we're only getting started. We've raised $6.6B in new funding at a $157B post-money valuation to accelerate progress on our mission. The new funding will allow us to double down on our leadership in frontier AI research, increase compute capacity, and continue building tools that help people solve hard problems. We aim to make advanced intelligence a widely accessible resource. We're grateful to our investors for their trust in us, and we look forward to working with our partners, developers, and the broader community to shape an AI-powered ecosystem and future that benefits everyone. By collaborating with key partners, including the U.S. and allied governments, we can unlock this technology's full potential," said OpenAI in a recent blog post... The Fly notes that OpenAI investors include Microsoft (MSFT) Japan's SoftBank (SFTBY), and AI chip maker Nvidia (NVDA). Reference Link

14:38 EDT Volkswagen of America reports Q3 sales increased 6% to 93,271 vehicles - Volkswagen of America released sales figures for Q3, reporting that sales increased 6% year-over-year to 93,271 vehicles, up from 87,756 units last year. Reference Link

13:48 EDT Establishment Labs jumps after first patients receive Motiva breast implants - Shares of Establishment Labs are moving higher after the company announced that the first patients in the United States have successfully undergone breast augmentation with Motiva Implants. CEO Juan Jose Chacon-Quiros said in a statement, "With the FDA approval last week, we are experiencing high demand for Motiva Implants - both from surgeons and patients. The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement. Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly. Everything we are seeing suggests that we can be the implant of choice in the United States." Shares of Establishment Labs are up 13% to $45.88 in midday trading.

13:17 EDT Arthur J. Gallagher acquires Risk International; terms not disclosed - Arthur J. Gallagher & Co. announced that its alternative risk and capital solutions subsidiary, Artex, has acquired Fairlawn, Ohio-based RIBV Holdings, LLC, and its subsidiaries, collectively doing business as Risk International. Terms of the transaction were not disclosed. Risk International provides outsourced risk management and employee benefits advisory services for private equity and corporate clients across the U.S.

13:12 EDT North American rail traffic up 0.3% for the week ending September 28 - The Association of American Railroads or AAR, reported U.S. rail traffic for the week ending September 28. For this week, total U.S. weekly rail traffic was 507,537 carloads and intermodal units, up 1.6% compared with the same week last year. Total carloads for the week ending September 28 were 227,046 carloads, down 3.5% compared with the same week in 2023, while U.S. weekly intermodal volume was 280,491 containers and trailers, up 6.2% compared to 2023. Four of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included grain, up 2,435 carloads, to 20,941; motor vehicles and parts, up 732 carloads, to 16,705; and petroleum and petroleum products, up 617 carloads, to 10,782. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 6,955 carloads, to 60,885; nonmetallic minerals, down 3,168 carloads, to 30,583; and metallic ores and metals, down 1,863 carloads, to 21,213. North American rail volume for the week ending September 28, on 9 reporting U.S., Canadian and Mexican railroads totaled 338,087 carloads, down 3.6% compared with the same week last year, and 362,754 intermodal units, up 4.2% compared with last year. Total combined weekly rail traffic in North America was 700,841 carloads and intermodal units, up 0.3%. North American rail volume for the first 39 weeks of 2024 was 25,999,318 carloads and intermodal units, up 2.5% compared with 2023. Publicly traded companies in the space include CN (CNI), CSX (CSX), Canadian Pacific Kansas City (CP), Norfolk Southern (NSC) Union Pacific (UNP), (TRN), Greenbrier (GBX), FreightCar America (RAIL), L.B. Foster (FSTR), Wabtec (WAB) and GATX (GATX). Reference Link

12:13 EDT Innovative Eyewear announces new retail partners - Innovative Eyewear announces a "successful Vision Expo West show resulting in new optical stores carrying its smart frames," bringing the total number of stores carrying the company's smart eyewear to approximately 370. Harrison Gross, CEO of Innovative Eyewear, said: "Retailer feedback on our newest frames has never been better, with visitors to the booth commenting on markedly improved comfort, fit and sound quality over previous generations of our products. The new wrap models from the Reebok and Lucyd Armor collections were particularly well-received, as stylish and affordable entries to the smart eyewear market, with the potential to expand our reach to new sectors of safety and sport glasses users worldwide. It was also a delight to see people interacting with our new Lucyd Kiosk displays. Vision Expo remains an important focal point for the industry, and we look forward to meeting and acquiring even more retail partners at the next one in Orlando."

12:02 EDT BMO appoints Kristin Milchanowski as chief AI, data officer - BMO announced the appointment of Kristin Milchanowski as its new Chief Artificial Intelligence and Data Officer, effective October 15, 2024. Kristin will drive BMO's Artificial Intelligence, data, analytics, and robotics strategies and supporting technologies, championing a transformative AI roadmap that optimizes and enhances business value. Additionally, she will focus on data management and data governance across the organization, deepening the bank's robust and established culture of innovation and accountability. Most recently, Kristin was a Global Innovation Partner / Principal at EY, focused on AI, High Process Computing and Quantum technologies.

12:01 EDT Joby Aviation rises 19.6% - Joby Aviation is up 19.6%, or 94c to $5.74.

12:01 EDT Agilon Health falls -11.7% - Agilon Health is down -11.7%, or -43c to $3.24.

12:00 EDT Humana falls -17.6% - Humana is down -17.6%, or -$49.06 to $230.39.

11:41 EDT Golden Sun Health Technology Group Ltd trading resumes

11:29 EDT Delta signs codeshare agreement with Saudia Airlines - Delta Air Lines signed a codeshare agreement with Saudia Airlines, the national flag carrier of Saudi Arabia. The agreement builds on the airlines' existing interline relationship and will expand the choice of destinations for Delta customers between North America and the Arabian Peninsula. The carriers have applied for necessary codesharing authority and will start selling codeshare itineraries once all government approvals have been received. The codeshare agreement will enable greater connectivity between the United States and the Middle East. Delta customers will gain access to nine destinations in Saudi Arabia and the Middle East beyond Saudia's hubs in Jeddah and Riyadh. Saudia guests will gain access to 12 destinations in the U.S. beyond Delta's hubs at JFK and LAX airports. The pact is subject to U.S. DOT government approval.

11:02 EDT BAE Systems awarded $6M Phase 2 contract from U.S. DARPA - The U.S. Defense Advanced Research Projects Agency has awarded BAE Systems a $6M Phase 2 contract to continue to develop software that autonomously configures tactical networks for mission-critical communications. The award follows Phase 1 of the Mission-Integrated Network Control program. The MINC program seeks to build and demonstrate an integrated, advanced capability that creates a secure communications network to support multi-domain operations. Under the terms of the Phase 2 contract, BAE Systems' FAST Labs research and development organization will continue to advance the algorithms and software that anticipate and dynamically adapt network services to dramatically improve mission outcomes.

10:37 EDT Hetero signs licensing agreement with Gilead expanding access to Lenacapavir - Hetero announced a new partnership with Gilead Sciences Ireland UC for a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries. This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to prevent HIV through pre-exposure prophylaxis. This collaboration marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV and offers a promising option for HIV prevention in underserved regions. Lenacapavir is a breakthrough HIV-1 capsid inhibitor that works with other antiretroviral drugs to treat multi-drug-resistant HIV-1 infections. It has a unique ability to target multiple stages of the HIV lifecycle, making it highly effective for patients with limited treatment options.

10:11 EDT Wheeler Real Estate Investment Trust trading resumes

10:01 EDT Walgreens Boots Alliance launches Student Loan 401(k) Match Program - Walgreens announced the launch of the Walgreens Student Loan 401(k) Match Program. This new benefit, available beginning in January 2025, will allow team members to qualify for company 401(k) match contributions as they pay down their student loans.

10:00 EDT X Financial rises 12.3% - X Financial is up 12.3%, or 91c to $8.30.

10:00 EDT TC Energy falls -8.8% - TC Energy is down -8.8%, or -$4.24 to $44.13.

10:00 EDT Humana falls -21.6% - Humana is down -21.6%, or -$60.44 to $219.01.

09:48 EDT TC Energy falls -8.4% - TC Energy is down -8.4%, or -$4.04 to $44.33.

09:47 EDT Gaotu Techedu rises 12.2% - Gaotu Techedu is up 12.2%, or 48c to $4.42.

09:47 EDT Joby Aviation rises 16.9% - Joby Aviation is up 16.9%, or 81c to $5.61.

09:35 EDT Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis - Immix Biopharma announced advances in the NEXICART-2 clinical study of its CAR-T NXC-201 for relapsed/refractory AL Amyloidosis, a plasma cell disorder that leads to progressive damage to the heart, kidney and liver, which currently affects approximately 33,000 patients in the U.S. Immix Biopharma's sterically-optimized CAR-T NXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials."We are pleased to report that the NEXICART-2 study is making excellent progress. We are now one step closer to providing a new treatment option for patients with relapsed/refractory AL Amyloidosis, where no FDA drugs are approved today," said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. "Robust enrollment reflects the enthusiasm of clinical investigators for CAR-T NXC-201." "Positive data from our ex-US study of NXC-201, the largest CAR-T clinical study in relapsed/refractory AL Amyloidosis to-date, showed a 92% overall response rate and a 28.0 month duration of response, presented at ASGCT 2024," said Gabriel Morris, Chief Financial Officer of Immix Biopharma. The NEXICART-2 study is intended to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients with adequate cardiac function who have not been exposed to prior BCMA-targeted therapy. Advancement to the second dosing cohort of three patients at 450 million CAR-T cells will dose one patient with NXC-201 every 28-days, subsequently enabling multiple patients to be dosed per month in NEXICART-2. Each of the NEXICART-2 dose levels have produced complete responses in relapsed/refractory AL Amyloidosis patients in the ex-U.S. NEXICART-1 study presented at ASGCT 2024.

09:26 EDT IntelGenx granted court approcal of sale proposal from Atai Life Sciences - IntelGenx Technologies (IGXT) announces that the Company and its subsidiary IntelGenx have obtained on September 30, 2024 an approval and vesting order from the Superior Court of Quebec issued in connection with the previously announced proceedings instituted pursuant to the Companies' Creditors Arrangement Act. The Approval and Vesting Order approved the previously announced transactions contemplated in the sale proposal from atai Life Sciences AG (ATAI), as well as the implementation of a reorganization of the IGX Entities that involves: the incorporation of two new entities to ultimately hold certain excluded liabilities of IGX and certain excluded assets, and the exchange of the shares of IGX, on a one-for-one basis, for common shares of New ParentCo. Pursuant to the Transaction, which closed on October 2, 2024, atai acquired all of the issued and outstanding shares of IGX. The Transaction was structured as a credit bid, whereby atai agreed that its senior secured debt in IntelGenx was discharged in exchange for IGX shares. No atai equity or cash was exchanged in connection with this Transaction. Based on the terms of the Transaction and the consideration received by New ParentCo, holders of the Company's shares will not receive any payments for, or distributions on, their shares in connection with the CCAA proceedings. It is also expected that the Company, Residual IGX and New ParentCo, entities that will hold the remaining assets and liabilities that atai chose not to purchase as part of the Transaction, will file for bankruptcy in the coming weeks under the laws of their respective jurisdictions.

09:24 EDT PharmAla to supply Harvard's Maclean Hospital with LaNeo MDMA - PharmAla Biotech has been contracted as a supplier of MDMA to a clinical trial at Harvard's Maclean Hospital, the largest neuroscientific and psychiatric private research hospital in the world.

09:19 EDT Cero Therapeutics appoints Al Kucharchuk as CFO, Kristen Pierce as CDO - CERo Therapeutics announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert "Al" Kucharchuk has been named CFO and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. Kucharchuk joins CERo from Nukkelous, Inc. and Chain Bridge I, Inc., both Nasdaq-traded companies where he served as CFO. Prior to joining CERo, Kristen was Vice President, Translational Medicine at Pionyr Therapeutics.

09:17 EDT American Rebel ships re-stocking order from Kansas' Standard Beverage - American Rebel Holdings announced their operating subsidiary American Rebel Beverages, received a multi-pallet re-stocking order for 12-packs of 12oz cans from Kansas' Standard Beverage. The Standard Beverage order was shipped from the Company's recently completed full production run of American Rebel Light Beer's 12 oz cans. Demand for American Rebel Premium Light Lager continues to build at a rapid pace and the Company continues to process new orders, reorders and distributor agreements, and will announce those as they are finalized.

09:12 EDT TNF Pharmaceuticals announces investment from Prevail Partners - TNF Pharmaceuticals announced that it has secured a strategic equity investment, priced at a 20% premium to a 30-trading days volume weighted average price, from Prevail Partner, a U.S. investment fund focused on life sciences companies. The company has engaged global full-service clinical research organization Prevail InfoWorks, Inc., an affiliate of Prevail Partners, to provide clinical services for the next Phase 2 clinical study using our proprietary drug in sarcopenia/frailty. Prevail Partners has agreed to purchase 283,019 shares of TNFA common stock at a price of $2.12 per share, representing a 20% premium to the company's 30-trading days VWAP as of the closing date of October 1, 2024.

09:11 EDT Eagle Pharmaceuticals commences review to evaluate range of alternatives - The company has commenced a review process to evaluate a range of potential financing and other alternatives to strengthen its liquidity position and capital structure. There is no deadline or definitive timetable for the completion of this process, and there can be no assurance as to its outcome. The company does not intend to disclose or comment on further developments with respect to this process unless and until it determines that further disclosure is required by law or it otherwise deems appropriate.

09:09 EDT Tesla falls 3% to $250.02 following Q3 production report

09:09 EDT Kazia Therapeutics announces presentation of Phase 1 data on paxalisib - Kazia Therapeutics announced the presentation of data from a Phase I study evaluating concurrent paxalisib and radiation therapy in patients for the treatment of solid tumor brain metastases or leptomeningeal metastases harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting, ASTRO 2024, which is taking place from September 29 - October 2, 2024, in Washington, D.C. Summary Results from Part II of Phase 1 Study: Concurrent daily administration of paxalisib with brain radiotherapy was generally well-tolerated at a maximum dose of 45 mg per day in advanced solid tumor patients with brain metastases and PI3K pathway mutations; The most commonly reported adverse events in the study were nausea, vomiting and hyperglycemia; Established proof-of-principle for molecularly-selected, rational combination studies in radiation oncology to assess safety and ultimately efficacy; Treatment with 45mg paxalisib and radiotherapy demonstrated a 67% PR; and Over two-thirds of the patients at MTD achieved intracranial response which compares favorably to historical response rates for WBRT alone.

09:07 EDT Eliem Therapeutics to change corporate name to Climb Bio - Eliem Therapeutics announced that it will change its corporate name to Climb Bio. The new name and corporate brand reflect the Company's new mission to develop a pipeline focused on immune-mediated diseases, following its acquisition of Tenet Medicines, Inc. In conjunction with the corporate name change, the Company will begin trading under the new ticker symbol "CLYM" on the Nasdaq Global Market at the open of the market on October 3. Budoprutug, formerly TNT119, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In a Phase 1b clinical trial of budoprutug in membranous nephropathy, 3 out of 5 of patients that received four doses of budoprutug achieved a complete remission of proteinuria, a primary symptom of membranous nephropathy.

09:06 EDT Grainger begins construction on massive distribution center - Grainger joined community members and officials from the greater Houston metropolitan area to ceremonially break ground for the company's 1.2 million-square-foot Houston Texas Distribution Center in Harris County on Tuesday, Oct. 1.

09:05 EDT Verizon appoints Santiago Tenorio as Chief Technology Officer - Verizon Communications announced the appointment of Santiago "Yago" Tenorio as Chief Technology Officer and SVP of Strategy and Technology Enablement. Tenorio brings more than 25 years of technical expertise in the wireless industry to lead the next chapter of Verizon technology innovation. Tenorio will report directly to Joe Russo, Executive Vice President & President, Global Network and Technology. Tenorio spent his 25-year career at Vodafone building high-performance teams and is recognized for his expertise in architecting Vodafone's Open RAN, Cloud Networking and Network APIs. He and his team oversaw all Network technology related decisions and defined the company's technology roadmap across mobile and fixed networks. Previously, he served as CTO for Vodafone Ireland and Chief Network Officer in the UK, successfully leading Vodafone's network coverage for the 2012 London Olympics.

09:05 EDT Amazon Business announces Business Prime Rewards, membership discount - Amazon Business announced Business Prime Rewards and a big discount to Business Prime Essentials membership. Business Prime Rewards is an exclusive benefit for Business Prime members giving business buyers the option to earn up to $1,000 annually on qualifying purchases while shopping on Amazon Business. Amazon Business customers with a personal Prime membership can access the first tier of Business Prime membership for free, or upgrade to the next tier for just $9.99 in their first year, at a discount of nearly 95%. New Business Prime members can also take advantage of this discount.

09:04 EDT Kyndryl launches services to speed adoption of AI-powered workplace solution - Kyndryl (KD) unveiled an expanded portfolio of services around Copilot for Microsoft (MSFT) 365 to speed AI adoption in the workplace. Microsoft Gen AI for the workplace by Kyndryl includes services that will help customers maximize the business impact of Copilot for Microsoft 365. Kyndryl's new services drive high-impact use cases by aligning data services, data extensibility, user interface design, and continuous improvement reporting. The services are designed to empower customers by enhancing decision-making, streamlining operations, and driving digital transformation, while accelerating deployment and adoption of Copilot for Microsoft 365 services

09:03 EDT Taboola announces partnership with Jounce Media - Taboola announced a partnership with Jounce Media, an industry leader in programmatic supply chain management, to verify that the Taboola Select publisher network is free from Made for Advertising properties. According to industry data, a substantial portion of advertising dollars are spent on Made for Advertising sites, with 15% of ad spend classified as MFA. Through this new partnership with Jounce Media, Taboola will utilize Jounce's MFA-detection technology and data, alongside proprietary machine learning models and procedures, to guarantee the exclusion of MFA publishers from Taboola Select.

09:02 EDT Gate's Cascade Investment sells 5.99M shares of CN - Cascade Investment announced that it has disposed of 5,994,691 common shares of CN by transferring ownership and control of the shares in a private transaction for no consideration. Following the disposition, Cascade owns 3,539,451 CN shares, representing approximately 0.56% of the issued and outstanding stock. As the sole member of Cascade, Bill Gates beneficially owns the shares owned by Cascade. In addition, the Bill & Melinda Gates Foundation Trust owns 54,826,786 common shares of CN, representing approximately 8.71% of the issued and outstanding stock.

08:56 EDT 5E Advanced Metals appoints Mark Zamek as VP, commercial products - 5E Advanced Materials announced the appointment of Mark Zamek to its senior leadership team. Mr. Zamek joins the Company as its Vice President of Commercial Products and brings more than 20 years of direct industry experience, having held various senior roles across Sales and Marketing functions at the largest global borate producers. Most recently, Mr. Zamek served as a consultant for Eti Maden where he advised the U.S.-focused boron operations on commercial strategy and market expansion initiatives.

08:51 EDT Catheter Precision announces update for VIVO non-invasive mapping system - Catheter Precision announced several updates for their VIVO non-invasive mapping system. Over the last 60 days and through the month of October the company has participated in several industry meetings where VIVO has been or will be highlighted. During the recent European Society of Cardiology meeting congress Professor Tarv Dhanjal from the University of Warwick Hospital in Coventry, UK, presented data of 20 patients from the "Accuracy of a non-invasive mapping system for the localisation of re-entrant VT site of origin and its relationship to myocardial scar on cross-sectional imaging" study. This study currently has 40 patients enrolled and is expected to enroll a total of 50 patients. It is anticipated that this final data to be available in 2025 and that the data will remain positive as enrollment and study conclusion comes to an end. Highlights of the most recent presentation include procedural success in 90% of patients at mean follow up of 7.3 +/- 4.7 months in patients with scar related VT.

08:50 EDT ALT5 Sigma to separate into two independent publicly-traded companies - ALT5 Sigma has announced a strategic plan to separate into two distinct companies. Following consummation of this plan, ALT5 will execute the separation of its Fintech and Biotech businesses, with ALT5 continuing as a leading fintech organization post-separation. The Biotech segment will emerge as Alyea Therapeutics Corporation, an independent firm dedicated to developing non-addictive pain management therapies. Upon separation, each company will present its own unique growth opportunities. As standalone entities, both companies are expected to benefit from: Increased focus and agility within their respective industries; Tailored capital allocation strategies to pursue differentiated strategic growth objectives; Enhanced strategic flexibility for portfolio-enhancing mergers and acquisitions; Unique investment profiles appealing to diverse investor bases; Distinct boards of directors and management teams dedicated to creating and increasing value in their respective sectors. The plan has been unanimously approved by the Company's board, following a thorough evaluation of alternatives that have been underway since the acquisition of fintech innovator ALT5 Sigma in May of this year. ALT5 will maintain its focus on blockchain-powered technologies that facilitate the transition to a new global financial paradigm. The Company offers two main platforms: "ALT5 Pay" and "ALT5 Prime." ALT5 Pay is a cryptocurrency payment gateway that enables registered and approved global merchants to accept and conduct cryptocurrency transactions or seamlessly integrate the ALT5 Pay platform into their applications or operations. ALT5 Prime is an electronic over-the-counter trading platform allowing registered and approved customers to buy and sell digital assets. It is accessible via browser-based applications, mobile apps, and through Broadridge Financial Solutions' NYFIX gateway for approved customers. Both ALT5 Pay and ALT5 Prime are experiencing increased customer engagement, with transaction volumes now exceeding $2 billion on an annualized basis. Alyea Therapeutics aims to become a leader in non-addictive pain management therapies. It intends to focus on indications of unmet medical needs and intends strategically to develop pathways to expedite approvals for its lead patented candidate, JAN123. This candidate is a Low Dose Naltrexone with a biphasic release formulation that the company plans to pursue through the FDA 505(b)(2) pathway. It has received orphan drug designation from the FDA, and, as a late-stage asset, the company intends to initiate a large-scale multicenter clinical trial to facilitate FDA approval through a New Drug Application. Simultaneously, Alyea Therapeutics will explore additional technologies to enhance its portfolio of non-opioid-based pain products. In connection with this realignment, the company is pleased to announce the appointment of Dr. Amol Soin as CEO of Alyea Therapeutics. Dr. Soin is the Chairman and founder of The Ohio Pain Clinic, a network of free-standing chronic pain management facilities in southwestern Ohio, focused on non-opioid treatments for chronic pain. Tony Giordano has been appointed Chief Science Officer of Aleaya Therapeutics. Most recently, he served as Senior Director of Special Projects in Cleveland Clinic Innovations, where he collaborated with staff to advance programs toward clinical application and commercialization. The company intends to hire additional management and appoint additional directors to both entities to bolster each respective company's teams with a focus on the unique specific needs for each entity.

08:46 EDT Black Hills Energy Arkansas receives approval for new rates - Black Hills announced that its Arkansas natural gas utility, Black Hills Energy Arkansas, received approval from the Arkansas Public Service Commission of a unanimous settlement agreement for new rates effective with October billing cycles. The new rates are designed to recover approximately $130 million of pipeline system investments since the utility's last general rate filing in 2021. The approved settlement agreement will generate approximately $25.4 million of new annual revenues and migrates approximately $3.7 million in annual rider revenue to base rates for a total annual base rate revenue increase of $29.1 million. The approval allows a 9.85% return on equity and a capital structure of 46% equity and 54% debt.

08:45 EDT M2i Global, NXT TEC partner for construction, critical mineral supply chains - M2i Global announced a strategic partnership with Perth-based NXT TEC. Ltd. This partnership aims to revolutionize construction and enhance the sustainability and security of critical mineral supply chains. M2i's ecosystem provides partners with access to turnkey solutions, facilitating expanded business opportunities, securing offtake agreements, influencing strategic government policy, engaging with aligned NGOs, and trusted laboratories. Through this partnership, M2i, NXT TEC. Ltd., and Not For Sale, M2i's exclusive human rights NGO partner, will work together to ensure positive social and labor impacts in the minerals and metals extraction space. By fostering ethical labor practices, the partnership will address the needs of local communities and contribute to a more sustainable future.

08:44 EDT Skyward Specialty Insurance expands renewable energy solutions - Skyward Specialty Insurance Group announced the expansion of its renewable energy solutions. As the renewable energy market continues to experience unprecedented growth, the need for specialized risk management solutions becomes increasingly important. However, many of these risks remain underserved by conventional coverage options. Skyward Specialty's expanded renewable energy offering now includes casualty coverage options targeting various renewable energy classes, including solar, wind, hydroelectric, biomass, and geothermal, providing tailored solutions for businesses in these sectors.

08:43 EDT OneMedNet announces strategic refresh of board of directors - OneMedNet announced a strategic refresh of its Board of Directors following the transition to a publicly traded entity. The company said, "This move reinforces our commitment to dynamic leadership and active engagement as we accelerate growth in this new phase.We extend our heartfelt gratitude to Paul Casey, and Erkan Akyuz for their invaluable contributions during a pivotal time in our company's history. Their leadership and guidance were instrumental in achieving our IPO, laying a strong foundation as OneMedNet entered the public markets. We thank them for their service and wish them the best in their future endeavors. In alignment with our vision for the future, we are excited to welcome two distinguished individuals to our Board." Jair Clarke, currently serves as Executive Advisor to the Chairman at World Wide Technology, holds the position of CEO at Laigic and is a board member of Xponential that is focused on health and wellness. Sherry Coonse McCraw, currently the VP of Human Resources and former CFO of BMW North America, brings a diverse background in both finance and human capital strategy.

08:42 EDT Enovix begins shipping batteries from its new Agility Line in Malaysia - Enovix announced that it commenced shipping EX-1M battery cell samples from its new Agility Line in Malaysia last week. This is an important milestone on the Company's journey to scale which follows shipping initial samples from Fab1 in California, and opening high-volume Fab2 in Malaysia just this summer. Enovix also recently completed internal UN38.3 certification for cells now shipping. UN38.3 is the United Nations standard for safe transportation of Lithium-ion batteries and is only granted to products that meet strict international safety and abuse tolerance standards through a series certified test protocol. By shipping samples within the third quarter of 2024, the Company is on track to commence high-volume production in 2025.

08:42 EDT ClearSign announces public release of California Statewide GET report - ClearSign Technologies, an emerging company in industrial combustion and sensing technologies that support decarbonization, improve operational and energy efficiency, enable the use of hydrogen as a fuel and enhance safety while dramatically reducing emissions announces that the Ultra low NOx Burner Testing study has been completed by the California Gas Emerging Technologies, GET, Program and that the final report prepared by ICF has been released to the public. The objective of the study sponsored by Southern California Gas Company was to test and quantify the emissions improvements and efficiency gains for the ClearSign Core-Rogue ultra-low NOx boiler burner compared to a conventional ultra-low-NOx burner operating in the same boiler.

08:41 EDT TerraZero announces beta Intraverse campaign for iGaming industry - TerraZero announced TerraZero's beta Intraverse campaign for the iGaming industry. TerraZero previously announced Intraverse PRO, a new subscription-based platform set to redefine how businesses, creators, artists, and individuals interact and engage within immersive 3D environments. TerraZero is now aiming to launch a beta campaign centered around the iGaming industry-presenting a new way for licensed operators, aggregators, and game developers across numerous markets to engage with new players in new ways using the Intraverse tech stack. TerraZero is welcoming entities across the industry to contact them directly to have a templated and customizable virtual iGaming environment designed and deployed for them. In these virtual environments: TerraZero provides a virtual experience front end, where users can click on different game machines that launch games to play in iFrames connected to partner servers; Games are hosted by licensed gaming entities, i.e. licensed operators, game aggregators, and other igaming affiliates, who will safely handle any user logins, any actual gameplay, and/or betting & reconciliation. From chat to iFrames with games, videos, third party content and more, TerraZero's Intraverse tech stack leverages a variety of features to help licensed operators, aggregators and game developers reach new users.

08:40 EDT Elevai Labs begins clinical study of topical exosome product - Elevai Labs announced the initiation of a clinical study to assess the efficacy of a topical exosome product in conjunction with an energy device treatment on facial skin appearance. The clinical study will assess the efficacy of Elevai's topical exosomes Elevai empower, a topical exosome serum designed specifically for in-office application, and Elevai enfinity, a daily topical exosome product for at home use, as standalone treatments and in conjunction with an energy device treatment on facial skin appearance. The objective of the study is to investigate the efficacy of a topical exosome product on facial appearance after daily use for up to 12 weeks. Elevai is collaborating with Dr. Jennifer Pearlman, an internationally recognized leader in regenerative and aesthetic medicine, and Medical Director of the PearlMD Rejuvenation clinic in Toronto, Canada. The study will enroll up to 20 healthy subjects between the ages of 35-75 years of age of Fitzpatrick skin types I-VI with mild to moderate facial photoaging and sensitive skin, including those with acne, rosacea, pigmentation issues, eczema, atopic dermatitis, dry skin, or cosmetic intolerance syndrome. Endpoints will measure tolerability for absence of skin irritation, safety, and statistically significant improvement in overall facial appearance 12 weeks as compared to baseline.

08:39 EDT Sealsq to showcase VaultC292 secure chip at CEATEC 2024 - SEALSQ will be demonstrating its secure solutions for Smart Home at the upcoming CEATEC 2024 event. The event will be held in Chiba, Japan from October 15 - 18, 2024 and showcase a comprehensive exhibition of digital innovation. As proud founding member of the Japanese branch of the Alliance, which develops global IoT/smart home standards such as Matter and Aliro, SEALSQ will be co-exhibiting at the Japan Smart Home Exhibition in Partners Park at booth number 3H097. SEALSQ's Japanese team, represented by Sales Director Katsunori Miyahata, will be showcasing the new VaultIC292 Secure Element pre-provisioned with certificates and keys ready for Matter connectivity. The chip will be presented inside a brand-new module designed for Home Automation applications and proposed to the Japanese market by SEALSQ's customer HOSIDEN, a major Japanese electronic components company. The VaultIC292 protects the Device Attestation Certificate of the module with the Matter stack running over Thread connectivity

08:38 EDT KULR Technology announces licensing agreement for its Xero Vibe technology - KULR Technology Group announced a licensing agreement for its proprietary vibration reduction technology named KULR Xero Vibe. The $2.35M landmark deal includes a $1.1M minimum guaranteed license and royalty fee, a unique opportunity for the licensee to purchase proprietary balancing equipment directly from KULR and additional revenue upside to KULR based on volume and technology upgrades. The licensee, a leading Japanese corporation, specializing in systems integration and the distribution of advanced semiconductor solutions, intends to use the KXV technology to balance industrial-scale fan systems used in data center computer cooling, HVAC and other industrial applications. KULR is exploring additional license opportunities based on geographic regions in tangential power-consuming applications, where KULR expects substantial upside revenue potential as product sales and royalty income scales along with its customers' growth.

08:37 EDT noco-noco announces amendments to resolutions for EGM - noco-noco would like to include a new proposal in addition to the original four proposals as set out in the Company's notice of EGM dated 22 August 2024 at the upcoming Extraordinary General Meeting, scheduled for October 7, 2024, at 9:00 A.M. The EGM will be held at 3 Temasek Avenue, Centennial Tower, Level 18, Singapore 039190. As previously communicated in the EGM notice published on August 22, 2024, the proposed amendments involve adjustments to Resolution Proposals 1 and 2, as detailed in the Proxy Statements distributed to shareholders. The Board has revised the language of these resolutions to specify the exact share consolidation ratio. The detailed wording of the Additional Proposal is included in Exhibit 99.2 of the 6-K filing by the Company.

08:36 EDT Yoshiharu closes $1M private placement equity investment - Yoshiharu Global announced the closing of a non-brokered $1.0 million private placement investment from an accredited investor and intends to use these proceeds for the Company's expansion into the Korean BBQ segment. As previously-announced, Yoshiharu has identified a growing trend of demand for KBBQ cuisine, predominantly in Southern California, as the popularity of Korean food has expanded American's rising appetites for Korean BBQ. Having operated in the restaurant sector since 2016, Yoshiharu has leveraged its extensive industry experience and expertise to build a robust network of supply chain stakeholders essential for successful restaurant operations. Recognizing the synergies between its existing suite of culinary offerings and the KBBQ concept, the Company plans to capitalize on the synergies of resources and ingredients for both segments to enhance purchasing power, attract a wider audience, and explore cross-promotion opportunities to further solidify and expand the Yoshiharu brand.

08:35 EDT Banzai receives non-compliance letter from Nasdaq - Banzai International announced that it received notice from the Nasdaq Listing Qualifications Panel of The Nasdaq Stock Market that the Hearings Panel has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before October 7, 2024, an application for listing on The Nasdaq Capital Market, and demonstrating compliance on or before January 31, 2025 with Listing Rules 5550. Notwithstanding the foregoing, there can be no assurance that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing.

08:33 EDT Actelis Networks awarded new order from major Italian motorways operator - Actelis Networks announced that it has received a new order for its cyber-hardened temperature hardened networking technology for a major Italian motorways operator. This order is an expansion of an order previously announced in June for an Italian National Transportation Infrastructure Project of over $300,000. Roadway safety is the top priority for the Italian operator, and Actelis' solution enables rapid modernization of their network infrastructure, expanding the use of critical safety tools like CCTV, speed cameras, sensors, and digital signage. Covering thousands of miles of roadways presents challenges, as these devices demand fast, secure, and reliable connectivity over long distances. Existing motorway wiring often falls short of handling the high data demands, which is why operators rely on Actelis for enhanced bandwidth and performance.

08:27 EDT Augmedix completes merger with Commure - Commure has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market.

08:22 EDT Alibaba repurchased 414M shares for $4.1B during Q1 under repurchase program - In a regulatory filing, Alibaba announced that during the quarter ended September 30, the company repurchased a total of 414 million ordinary shares, equivalent to 52 million ADSs, for a total of $4.1B. These purchases were made in both the U.S. and Hong Kong markets under its share repurchase program, Alibaba said. As of September 30, Alibaba said it had 18,620 million ordinary shares, equivalent to 2,327 million ADSs, outstanding, a net decrease of 405 million ordinary shares compared to June 30, or a 2.1% net reduction in its outstanding shares after accounting for shares issued under its ESOP.

08:20 EDT Charles River, Lundbeck in deal to use Logica for neurological disease drugs - Charles River Laboratories announced an agreement with H. Lundbeck o utilize Logica to progress critical brain disease research. "We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease," said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. "Logica's integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck's industry-leading neurology expertise, we look forward to a successful collaboration." Logica is an Artificial Intelligence powered end-to-end drug discovery solution that translates biological insights into optimized preclinical candidates by leveraging the integration of Valo Health's AI-powered Opal Computational Platform(TM) and Charles River's leading expertise in drug discovery and preclinical development. Through the agreement, Lundbeck will deploy Logica with the aim of creating optimized small molecules that lead to novel therapies for neurological research.

08:19 EDT Alaska Air, UP.Labs launch first new startup, Odysee - Alaska Airlines and UP.Labs, have officially announced their first new startup, Odysee, at the UP.Summit. Odysee, which launched with $5M in seed funding led by UP.Partners, is focused on lending powerful AI and computing power to inform real-time tradeoff decisions in planning for and managing operational logistics, starting with scheduling. The platform will ensure the best use of each aircraft asset and the interconnections between them, empowering teams to more effectively optimize one of the most complex areas of an airline's business.

08:17 EDT Vislink launches new brand identity, website - Vislink Technologies announced the unveiling of its modernized brand identity and completely redesigned website. This new digital marketing presence aims to elevate brand awareness, differentiate Vislink from its competitors, and provide customers with an enhanced, user-friendly platform that simplifies finding and understanding the company's market-leading solutions. The new brand and website are key elements in Vislink's marketing strategy to support the company's revenue growth goals. The new website at www.vislink.com offers a sleek, modern interface with enhanced navigation that allows customers to easily discover Vislink's comprehensive range of live video solutions spanning airborne video downlink systems, wireless video camera systems, bonded cellular solutions and AI video production. With detailed product information, case studies, and user-friendly access to resources, the platform is designed to serve as a one-stop destination for broadcasters, public safety professionals, and defense clients seeking innovative, reliable video communication solutions.

08:16 EDT AbbVie's Allergan Aesthetics announces national availability of JUV????DERM - Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVEDERM VOLUME XC for temple hollowing. Following its U.S. FDA approval in March 2024, JUVEDERM VOLUMA XC is the first and only hyaluronic acid filler approved to treat moderate to severe temple hollowing in adults over 21. The JUVEDERM(R) Collection of Fillers is the number one chosen HA dermal filler brand by patients and providers, and now offers the largest range of treatment indications to meet patients' aesthetic goals.

08:16 EDT Establishment Labs: 1st US women successfully receive BA with Motiva implants - Establishment Labs Holdings announced that the first patients in the United States have successfully undergone breast augmentation with Motiva mplants. "With the FDA approval last week, we are experiencing high demand for Motiva Implants - both from surgeons and patients," said Juan Jose Chacon-Quiros, Founder and Chief Executive Officer of Establishment Labs. "The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement. Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly. Everything we are seeing suggests that we can be the implant of choice in the United States."

08:14 EDT Primech Holdings signs several contracts with a total value of $4.3M - Primech Holdings announced several newly signed contracts, signaling robust growth and expanding opportunities across multiple sectors. With a total value exceeding $4.3M these new agreements underscore Primech's ongoing commitment to delivering exceptional facility services that consistently exceed each client's and sector's unique demands. The latest contract wins include: Secured a 5-year contract valued at $3.54M for cleaning and pest control services at a major biomedical research hub, one of Singapore's leading research facilities. Effective from June 2024 to May 2029, this agreement strengthens Primech's foothold in the scientific and research sector. Secured a 2-year contract effective October worth $419,160 for cleaning services with a private residential condominium development consisting of several high-rise blocks with modern facilities. This collaboration reinforces Primech's strong presence in the residential sector and showcases its continued growth in servicing premium residential communities. Secured a 1-year contract with a residential condominium development located in the Bukit Timah area of Singapore, an upscale and well-known residential district, to provide cleaning services valued at $167,571, commencing in September. This contract adds to Primech's already expansive portfolio of high-end residential properties. Secured a 2-year contract in July 2024 valued at $23,184 for providing cleaning services to an important non-profit social service institution that supports vulnerable individuals and families, further strengthening Primech's role in the welfare sector.

08:13 EDT UroGen Pharma: Patient dosed in mitomycin-based UGN-103 trial for LG-IR-NMIBC - UroGen Pharma announced that the first patient was dosed in the Phase 3 clinical trial of investigational drug UGN-103 , mitomycin for intravesical solution in development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer or LG-IR-NMIBC . UGN-103 is a next-generation novel mitomycin-based formulation. "Reaching this Phase 3 trial milestone for UGN-103 highlights our drive to innovate and bring forward cutting-edge treatments for low-grade intermediate-risk non-muscle invasive bladder cancer," said Liz Barrett, President and Chief Executive Officer, UroGen. "UGN-103 represents a significant step forward, offering potential improvements in manufacturing, convenience, and cost. We are excited about the potential of this next-generation formulation and look forward to furthering its development to advance the care of patients."

08:12 EDT Centene announces Ambetter health insurance offerings for 2025 - Ambetter, a product offered by Centene Corporation, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace, is announcing its affordable health plans for 2025. In many states, it is expanding its offerings. The different plans include: Ambetter Health of Delaware; Ambetter from WellCare of Kentucky; Ambetter from PA Health & Wellness; Ambetter of Alabama; Ambetter from Home State Health, Missouri; Ambetter from Meridian, Michigan; Ambetter Health, Florida; Ambetter from Sunflower Health Plan, Kansas; Ambetter from Arizona; Ambetter Health, Georgia; Ambetter from Coordinated Care, Washington State; and Ambetter from Louisiana Healthcare Connections; Ambetter from Fidelis Care, New York; Ambetter from SilverSummit Healthplan, Nevada; Ambetter of Oklahoma; Ambetter from Magnolia Health, Mississippi; Ambetter from Absolute Total Care, South Carolinians; Ambetter of Illinois; Ambetter of North Carolina; Ambetter from NH; Ambetter Health, Indiana; Ambetter Health, Iowa; Ambetter from Nebraska; Ambetter from Buckeye Health Plan, ohio; Ambetter from Superior HealthPlan, Texas; Ambetter from Health Net, California; Ambetter Health, Iowa.

08:12 EDT Outbrain announces beta launch of 'Moments' video solution - Outbrain announced the beta launch of Moments by Outbrain - a new way for users to interact with content, delivering the immersive experience of full screen vertical video browsing to the open internet. Moments enables traditional publishers and media owners to reimagine their online experience by transforming real estate on static articles into engaging vertical video feeds, bringing easy swipeable navigation to trusted, professional environments. Audiences are spending an increasing amount of their time within walled gardens and social platforms. Moments marks the development of a true solution to bring similar algorithm-powered, visual exploration to the open internet. The new product offering brings the viral video and social media experience directly to quality publishers like Fortune and Axel Springer. With Moments, audiences have a new way to watch, read, and explore the vast amount of professionally-produced editorial content on the open internet in an environment not yet seen beyond walled gardens. In addition, Moments provides advertisers with a rich new canvas to extend the power of social formats to drive outcomes on the open internet, while offering publishers an entirely new channel to grow and engage their reader base. Moments is currently in Beta and is being tested with selected partners in the USA, Germany, the UK, Italy, France, and Spain. A global launch is planned for 2025.

08:08 EDT ImmunoPrecise and Biotheus in MTEA pertaining to Talem therapeutic antibody - ImmunoPrecise Antibodies and Biotheus jointly announce that the two parties have entered into a Material Transfer and Evaluation Agreement or MTEA pertaining to a Talem therapeutic antibody asset for the development of a bispecific therapy against solid tumors. Under this MTEA, Biotheus will obtain the rights to further evaluate the suitability of Talem's Artificial Intelligence enhanced TATX-20 lead candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors.Under this agreement, Biotheus will receive a specialized antibody asset from Talem Therapeutics, a subsidiary of ImmunoPrecise Antibodies. Biotheus plans to use this asset in conjunction with its own proprietary technology and binders to develop a new class of cancer-fighting drugs. ...The transfer of this therapeutic asset to Biotheus aims to accelerate the development of targeted therapies that could potentially improve outcomes for patients with solid tumors. Following the transfer, Biotheus will evaluate the TATX-20 lead candidate. If the evaluation proves successful, Biotheus intends to further develop the bispecific molecules, with the objective of creating a clinically successful product that addresses the challenges associated with treating hypoxic solid tumors resistant to current therapies.

08:07 EDT Tactile Systems launches next-generation Nimbl platform - Tactile Systems Technology announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding approval from the Centers for Medicare & Medicaid Services in September 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months. Nimbl is 68% lighter, 40% smaller, and uses 33% less hosing than the Company's current generation basic pneumatic compression device. Its compact design is the smallest PCD of its kind, making it an ideal therapy for daily use at home or on the go. In addition to the patient centric feature enhancements, Nimbl also offers connectivity to the Company's free Kylee digital application, providing patients a simple way to track their usage and change in symptoms, and to share results with their care team. Convenient accessories are available for purchase including a rechargeable battery and custom-designed travel bag.

08:06 EDT Golden Matrix amends earnout structure of share purchase agreement - Golden Matrix Group passed its fifth amendment to the initial share purchase agreement with Meridianbet in connection with the Company's previous acquisition of Meridianbet earlier this year. Under the current Purchase Agreement, Golden Matrix is obligated to pay Aleksandar Milovanovic, Zoran Milosevic and Snezana Bozoviv additional sums of cash and Golden Matrix Common Stock within five business days following October 9, 2024. As of 1st October 1, 2024, the Share Purchase Agreement was amended to reflect that the cash component shall be paid to each of the Sellers as follows: Milovanovic - 40% of the total post-closing cash consideration due to Milovanovic shall be satisfied in shares of Golden Matrix Common Stock and the remaining contingent post-closing cash consideration shall be deferred until at least November 9, 2024. Milosevic - 40% of the total post-closing cash consideration due to Milosevic shall be satisfied in shares of Golden Matrix Common Stock and the remaining contingent post-closing cash consideration shall be payable at the rate of $50,000 per month, on each of October 1, 2024, November 1, 2024 and December 1, 2024. Bozovic - 20% of the total of the post-closing cash consideration due to Bozovic shall be satisfied in shares of Golden Matrix Common Stock and the remaining contingent post-closing cash consideration shall be payable at the rate of $50,000 per month, on each of October 1, 2024 and November 1, 2024. These conversions from contingent cash payments to Golden Matrix Common Stock aligns the interests of key stakeholders with GMGI's long-term prospects for further growth and overall continued success. Moreover, it is expected to provide GMGI with enhanced financial flexibility as it continues to focus on its various strategic initiatives and expansion efforts.

08:04 EDT Humana plunges after warning on 2026 revenue headwind from lower Star ratings - In a regulatory filing this morning, Humana states: "Based on preliminary 2025 Medicare Advantage - MA - Star Ratings data provided by the Centers for Medicare and Medicaid Services, or CMS, which became available in CMS Plan Finder as of October 1, 2024, Humana has approximately 1.6 million, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, a reduction from 94% in 2024. A significant driver of these results was contract H5216 decreasing to a 3.5-star rating from a 4.5-star rating in 2024. H5216 contains approximately 45% of Humana's MA membership, including greater than 90% of its employer group waiver plan - Group MA - membership. The decline in Stars performance for 2025 will impact Humana's quality bonus payments in 2026. 2025 Star rating details are expected to be formally released by CMS on or around October 10th. Based on the Company's review of the preliminary data provided by CMS, its reduction in Star ratings was driven by narrowly missing higher industry cut points on a small number of measures. Humana believes there may be potential errors in CMS' calculation of certain of its results and industry threshold cut points. The Company has outstanding appeals related to certain results and has requested additional information to ensure accuracy of threshold calculations. The Company intends to continue to engage with CMS on these matters to ensure Star ratings are accurate and representative of plan quality. Despite on-going appeal efforts, the Company is disappointed with its performance and has initiatives underway focused on improving its operating discipline and returning to an industry leading Stars position as quickly as possible. These initiatives are expected to impact performance across key measures and drive improved quality bonus payments in 2027 and beyond. Areas of focus include enhancing member and provider engagement strategies, improving customer experience and strengthening technology integrations to support operational excellence. The Company will provide additional detail regarding these initiatives over the coming months to further enhance its operating rigor. Humana is exploring all available options to mitigate the expected 2026 revenue headwind related to its 2025 Star ratings in the event its challenges to the results are unsuccessful. The 2025 Stars results are not expected to impact the Company's financial results or outlook for 2024 or 2025. In addition, the Company remains focused on achieving its individual MA margin target of 'at least 3 percent', although there is now more risk in its ability to fully achieve this result by 2027. Finally, the Company is focused on realizing its full potential by concentrating on continuous improvement and leveraging its differentiated capabilities to improve the health of its customers and drive long-term shareholder value." Humana shares, which declined nearly 12% on Tuesday to close at $279.45, are indicated down another 22% to $219.29 in Wednesday pre-market trading.

08:03 EDT Accenture, Nvidia announce expanded partnership - Accenture (ACN) and Nvidia (NVDA) announced an expanded partnership, including Accenture's formation of a new Nvidia Business Group. With generative AI demand driving $3B in Accenture bookings in its recently-closed fiscal year, the new group will help clients lay the foundation for agentic AI functionality using Accenture's AI Refinery, which uses the full Nvidia AI stack-including Nvidia AI Foundry, Nvidia AI Enterprise and Nvidia Omniverse-to advance areas such as process reinvention, AI-powered simulation and sovereign AI. Accenture AI Refinery will be available on all public and private cloud platforms and will integrate with other Accenture Business Groups to accelerate AI across the SaaS and Cloud AI ecosystem.

08:03 EDT aTyr Pharma announces publication of Phase 1b/2a clinical trial ofefzofitimod - aTyr Pharma announced the publication of a post hoc analysis of the Phase 1b/2a clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in the European Respiratory Journal. The publication is entitled "Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis." The publication reports findings from a post hoc analysis of a pre-specified endpoint in the Phase 1b/2a randomized, double-blind, placebo-controlled, 24-week study of efzofitimod in 37 patients with pulmonary sarcoidosis receiving oral corticosteroid treatment who underwent a forced steroid taper in the first 8 weeks of the study. In this pooled analysis, the time-to-first-relapse was significantly shorter in the subtherapeutic group than in the therapeutic group. The median time-to-first-relapse in the subtherapeutic group was 126 days, whereas only one of 17 patients in the therapeutic group had relapsed by the end of the study. Furthermore, 54.4% of patients in the subtherapeutic group relapsed for steroid use following steroid taper, compared to 7.7% of patients in the therapeutic group. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. Efzofitimod is currently being investigated in the global pivotal Phase 3 EFZO-FIT study in 268 pulmonary sarcoidosis patients Efzofitimod has received orphan drug designation in the U.S., E.U. and Japan for sarcoidosis and Fast Track designation in the U.S. for pulmonary sarcoidosis. The Phase 1b/2a study was a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial in 37 patients with pulmonary sarcoidosis.

08:02 EDT NaaS joins China ESG alliance - NaaS Technology announced that it has joined the China ESG Alliance as the first member from China's electric vehicle charging sector. This strategic move highlights NaaS's dedication to advancing sustainable practices and enhancing green, low-carbon initiatives across the industry.

07:41 EDT Alterity Therapeutics presents data on ATH434 at MDS Congress - Alterity Therapeutics announced that multiple oral and poster presentations were presented at the International Congress of Parkinson's Disease and Movement Disorders. Title: Preliminary Efficacy and Safety of ATH434 in Multiple System Atrophy: Results: The interim data suggest that ATH434 may have a disease-modifying effect in MSA, with 30% of participants showing stable or improved clinical outcomes. The average change in Unified MSA Rating Scale Part I scores over 6 months is smaller than typically observed in untreated MSA patients. At 6 months all participants exhibited brain volume declines consistent with MSA progression; however, the clinical responders maintained stable brain volumes at 12 months. Importantly, ATH434 was well tolerated with no drug-related serious adverse events, and most adverse events were mild to moderate, showing a favorable safety profile. Together, these early outcomes suggest that ATH434 could have a potential to modify disease progression. Neurofilament light chain levels are a measure of neuronal injury and are often correlated with disease severity. In the Phase 2 trial, the clinical responders had stable or reduced NfL levels: at 6 months, the average increases in NfL were 2.7% in CSF and 4.5% in plasma, compared to 17.9% and 19.3% in Alterity's bioMUSE natural history participants, respectively. In addition, clinical responders also showed stability in iron levels in the substantia nigra, putamen, and globus pallidus compared to non-responders with increased iron. The stabilization of iron content in these subcortical brain regions, combined with NfL biomarker data, indicates that ATH434 may slow neurodegeneration by modulating brain iron levels and reducing oxidative injury. Title: A Phase 2 Study of ATH434, a Novel Inhibitor of alpha-Synuclein Aggregation, for the Treatment of Multiple System Atrophy: Results: The oral presentation and poster describe the baseline characteristics for the 77 participants from Alterity's ATH434-201 randomized, double-blind Phase 2 clinical trial, with a focus on baseline fluid biomarkers, neuroimaging and clinical data. The participants met strict selection criteria designed to confirm that participants had early-stage MSA. The accuracy of diagnosing clinically probable MSA may be increased using a multimodal approach that includes neuroimaging biomarkers and fluid biomarkers such as NfL. ATH434 is a potential disease modifying therapy based on its ability to redistribute excess labile iron without impairing normal iron storage, inhibit alpha-synuclein aggregation and reduce oxidative injury. Importantly, increased iron levels were evident in multiple subcortical brain regions, with increased levels being observed in the substantia nigra in nearly all subjects. Title: Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation: Results: The poster describes results from the "Biomarkers of progression in Multiple System Atrophy" natural history study designed to track the progression of individuals with MSA. For participants enrolled in bioMUSE, fluid and imaging biomarkers, along with clinical manifestations, were used to classify patients as MSA or Parkinson's Disease/Dementia with Lewy Bodies. Patients who tested negative for alpha-synuclein were excluded from the analyses. In the trial, novel MRI imaging techniques and deep learning segmentation were used to assess brain volume across brain Regions of Interest relevant to MSA. Structural MRI plays a critical role in both diagnosing MSA and monitoring disease progression. Subcortical brain volume shows potential as a biomarker for evaluating disease-modifying therapies. Over the course of one year, MRI with deep-learning segmentation revealed significant brain volume reduction in MSA ROIs whereas the PD patients showed no significant brain volume changes. In contrast, the MSA patients exhibited significant volume reductions in the cerebellum, globus pallidus, and brainstem. In addition, the MSA-P patients showed significant volume loss in the putamen. The results illustrate the correlation between the brain volume reduction and worsening clinical scores, as measured by the UMSARS, providing a visual representation of disease progression. Title: Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson's Disease Model in Macaques: Results: The presentation demonstrated that ATH434 treatment led to lower iron levels in the affected area of the brain, the substantia nigra, and improved motor performance and general function in monkeys with experimentally induced Parkinson's disease. At week 12, all 5 ATH434-treated macaques had stable or improving scores from Baseline while two of three vehicle-treated macaques did not demonstrate improvement. The improved general behavior was well-correlated with reduced motor impairment. These favorable parkinsonian outcomes observed in each of the ATH434-treated monkeys were also associated with increased levels of striatal synaptophysin, a protein marker that reflects functional connections between neurons, suggesting functional recovery of nerve endings in this critical motor pathway. These results support further investigation of ATH434 for the treatment of Parkinson's disease.

07:38 EDT Rio2 Limited subsidiary receives the principal Sectorial Permits in Chile - Rio2 announces that its Chilean subsidiary, Fenix Gold Limitada, has received the principal Sectorial Permits it requires to begin construction at its Fenix Gold Project located in the Maricunga Gold Belt of the Atacama Region, Chile. These Sectorial Permits are: Mining Methods; Process Plant; Waste Dumps & Stockpiles; and Closure Plan. These Sectorial Permits represent the last governmental authorization required to enable the start of the construction phase and subsequent operation of the Fenix Gold Mine. Following the announcement of the filing of an independent technical report dated October 16, 2023, entitled "NI 43-101 Technical Report on the Feasibility Study for the Fenix Gold Project", Rio2 has been working with its financial advisor, Endeavour Financial, to develop the optimum financing solution for the Fenix Gold Project. The Company has received several financing proposals from interested counterparties, which are being considered by management and the Company's Board. Due diligence is progressing with certain of these financing sources and further updates will be provided in due course. The Fenix Gold project is one of the largest undeveloped gold oxide, heap leach projects in the Americas, hosting a Measured and Indicated mineral resource of 4.8M ounces of gold which the Company believes will make a positive contribution to the Atacama Region and Chile. The Project is an example of modern gold mining where a full complement of technical, environmental, and social considerations has been consulted on and designed in from the outset. The Project represents a significant investment in the gold mining business in Chile by a junior mining company of approximately $235M of initial and sustaining capital and will generate employment for at least 1,200 people during the construction phase and 800 people during the 17-year operations phase.

07:36 EDT CME Group reports Q3, September market statistics - CME Group reported its Q3 and September 2024 market statistics, with average daily volume reaching new, all-time records of 28.3 million contracts in Q3 and 28.4 million contracts in the month of September, and growth across all asset classes in both periods. In Q3, the company's ADV grew 27% year-over-year, with record volume in interest rate products. CME Group's deeply liquid U.S. Treasury complex hit an all-time quarterly ADV record of 8.4 million contracts and SOFR futures reached an all-time quarterly ADV record of 4.1 million contracts. September ADV grew 25% year-over-year, with record volume in interest rate and agricultural products for the month.

07:35 EDT Titan Medical announces director resignations - Titan Medical announces that following its annual general meeting held on September 30, 2024 and in accordance with Titan's Majority Voting Policy, Anthony Giovinazzo, Cathy Steiner, Cary Vance and Paul Cataford have tendered to the Board of Directors their resignations as directors of Titan. Pursuant to the Voting Policy, the Corporate Governance and Nominating Committee of the Corporation must consider such resignations and make a recommendation to the Board as to whether to accept such resignations within ninety days of the Meeting. In its deliberations, the Committee may consider, among other things, the effect any resignation may have on the Corporation's ability to comply with any applicable governance rules and policies. In accordance with Titan's Articles and corporate law requirements, Titan must have a minimum of three directors and under the applicable securities instrument governing audit committees, Titan's audit committee must currently comprise a minimum of three independent directors. As a result of the foregoing, the Board has only accepted Paul Cataford and Cary Vance's resignations with immediate effect at this time.

07:33 EDT Verrica Pharmaceuticals to reduce number of sales territories to 35 from 80 - Verrica Pharmaceuticals announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH for the treatment of molluscum contagiosum. These operational changes to Verrica's commercial organization are expected to reduce the Company's overall cost structure by approximately fifty percent, while maintaining sufficient resources to support YCANTH as the new standard of care for patients with molluscum contagiosum. To reduce expenses and optimize the efficiency of Verrica's field force, the Company will reduce the number of sales territories from 80 to approximately 35, with a focus on those territories that have historically shown a high prevalence of molluscum, a critical mass of previous cantharidin users and strong insurance coverage for YCANTH. Sales activities in each of these territories will focus on pediatricians in addition to Verrica's established sales efforts to dermatology offices. The Company will also reduce headcount in certain support functions. Total operating expenses after the restructuring are expected to be reduced by approximately fifty percent. The Company will incur a one-time charge related to the restructuring of approximately $1.0 million.

07:31 EDT Eli Lilly announces new $4.5B site, the Lilly Medicine Foundry - Eli Lilly and Company announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. This facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials. The first-ever facility of its kind, combining research and manufacturing in a single location, the Medicine Foundry will be located in Indiana's LEAP Research and Innovation District in Lebanon, Indiana, and will expand the company's investment there to more than $13 billion. "As we accelerate our work to discover new medicines for the toughest diseases, we're continuing to invest in state-of-the-art infrastructure to support our growing pipeline," said David A. Ricks, Lilly's chair and CEO. "In addition to supplying high-quality medicine for our clinical studies, this new complex will further strengthen our process development and scale up our manufacturing capabilities to speed delivery of next-generation medicines to patients around the world."

07:17 EDT Veeva announces 18 of top 20 medtech companies use its Cloud applications - Veeva Systems announced that 18 of the top 20 medtech companies leverage Veeva Development Cloud and Veeva Commercial Cloud applications to streamline processes across the total medtech product lifecycle. Veeva MedTech enables more than 125 customers with deep industry expertise and technology from ideation to commercialization. With an increasing need to keep up with industry changes for faster time to market, medtech companies are moving to connected applications on a single cloud platform to execute key processes more efficiently.

07:13 EDT Energy Fuels completes acquisition of Base Resources - Energy Fuels announced that it has completed the acquisition of Base Resources, an established heavy mineral sands and critical mineral company, headquartered in Perth, Australia, in consideration of the issuance of Energy Fuels shares totaling approximately $178.4M in value. "With Energy Fuels' acquisition of Base Resources and its Toliara Project in Madagascar, we have now acquired the raw materials that, when developed, will enable us to become one of the world's leading suppliers of advanced rare earth products and titanium and zirconium minerals, while also maintaining our current position as a leading producer of uranium in the United States," said Mark Chalmers, President and CEO of Energy Fuels Inc.

07:09 EDT SM Energy announces closing of Uinta acquisitions - SM Energy Company announced that it has closed the previously announced Uinta Basin acquisition of an 80% undivided interest in the oil and gas assets of XCL Resources, LLC and affiliated entities, which includes the exercise of its option to acquire certain additional assets adjacent to XCL Resources position. President and Chief Executive Officer Herb Vogel comments: "We are excited to add a third core area of very high-quality assets to the SM portfolio. We look forward to welcoming new employees to the SM team from XCL Resources and Altamont Energy and to working in our new Utah communities. The Uinta Acquisitions add significant scale and long-term value creation opportunity for SM Energy via high-quality, oily stacked pay with outstanding well economics."

07:07 EDT Tilray's Blue Point Brewing hosts 20th Annual Cask Ales Festival - Blue Point Brewing Company announces its 20th Annual Cask Ales Festival, taking place on Saturday, Nov. 2, 2024 from 2pm - 6pm at its flagship brewery in Patchogue, New York. The milestone event promises to be the biggest celebration yet, featuring live performances by The Warped Tour Band, KRUSH, and DJ Kaution, along with a full day of entertainment, exceptional beer tastings, delicious food trucks, and exciting surprises.

07:06 EDT Marex Group to acquire Aarna Capital, terms not disclosed - Marex Group has agreed to acquire Aarna Capital to expand its operations in the Middle East and grow its clearing business, in line with its strategy to broaden its client base, diversify its operations and increase earnings resilience. Based in Abu Dhabi, Aarna Capital provides clearing, execution and customised risk management solutions in energy, base and ferrous metals, as well as financial markets such as equities, fixed income and FX. The acquisition of Aarna Capital will provide Marex with additional capabilities in a new location and access to around 180 local clients, which includes institutional investors, family offices and corporate clients, through a well-established and respected team. The acquisition will be highly complementary to Marex's existing operations in the Middle East, which includes approximately 60 employees in Dubai, and is aligned with Marex's strategy to bring new clients to its platform, increase the capabilities it can offer existing clients, and grow its global footprint. The transaction is expected to be accretive to earnings and contribute around five percent of Marex Group's profit after tax from fiscal year ended 31 December 2025 onwards. This includes anticipated day one synergies from Aarna Capital's business activity flowing through the Marex platform, with savings from internalising clearing fees and higher net interest income through Marex's financing relationships. In addition, Marex has identified significant scope for future growth by adding new clients in the Middle East through these additional capabilities and from cross-selling Aarna Capital's products to existing clients. This acquisition is expected to close in late 2024, subject to regulatory approval.

07:05 EDT BioCryst begins enrollment for Phase 1 trial evaluating BCX17725 - BioCryst Pharmaceuticals announced the enrollment of the first participant in a Phase 1 trial evaluating BCX17725, a potent and selective investigational kallikrein 5, or KLK5, inhibitor designed to provide best-in-class disease-modifying treatment for people with Netherton syndrome. BCX17725 is a protein therapeutic that is designed to treat the underlying protein deficiency that causes Netherton syndrome by inhibiting KLK5, a serine protease in the skin that is unregulated in people with Netherton syndrome. The trial will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants, and multiple doses in participants with Netherton syndrome in an open-label design. The company expects to report initial results from the trial by the end of 2025. Netherton syndrome is a serious, rare, lifelong genetic disorder affecting the skin, hair, and immune system, caused by lack of normal function of a natural inhibitor of KLK5. People with Netherton syndrome often have red, scaly, inflamed skin, fragile hair, and are more likely to develop skin infections, allergies, asthma and eczema. Netherton syndrome can be life threatening, especially during infancy when patients are vulnerable to dehydration and recurrent infections. Currently, there are no approved treatments for Netherton syndrome.

07:04 EDT WiSA Technologies hires Stanley Mbugua as VP of Finance, CAO - WiSA Technologies has hired Stanley Mbugua as Vice President of Finance, effective September 30. In a planned transition, he will also assume the role of Chief Accounting Officer, effective November 30 . Mr. Mbugua will be responsible for performing the services and duties customarily associated with both the Vice President of Finance and Chief Accounting Officer positions. "We are building our team for the next phase of growth, and we welcome Stanley in his current role as VP Finance and planned transition to also assume the role of Chief Accounting Officer," said Brett Moyer, CEO of WiSA Technologies. "Stanley brings extensive experience and a proven track record in leading financial operations with multinational technology companies, and we are confident he will play a pivotal role in shaping the financial future of WiSA."

07:03 EDT Mobilicom awarded order from Tier-1 Israel-based customer - Mobilicom (MOB) announced it has secured its third production-scale order from a Tier-1 Israel-based customer, bringing total purchases from this customer to $1.7M in less than a year. The customer, one of the world's largest loitering munitions providers with approximately $4B in annual revenue, has selected Mobilicom's SkyHopper Pro Micro datalink for integration into its systems. This latest order is valued at $530,000. This Tier-1 customer is a prime vendor for Lockheed Martin (LMT) in the U.S. and a major supplier of defense systems, including loitering munitions, sold to over 40 countries, including European Union and NATO member countries. With EU defense spending rising dramatically due to the conflict in Ukraine, this vendor has achieved significant success and market share with its loitering munitions, becoming a key player in meeting the growing demand for advanced military technologies in Europe and beyond. SkyHopper PRO Micro, Mobilicom's newest secured software defined radio, currently offers the best size-to-performance form factor in the industry at 50% of the size of the closest comparable competitor and at a fraction of the price. The product was designed in collaboration with this Tier-1 customer with the aim of supporting mass production. SkyHopper Pro Micro can be upgraded with Mobilicom's ICE Cybersecurity suite which can withstand current threats seen in conflicts around the world.

07:02 EDT CGI selected a position of the FCHS2 10-year IDIQ contract by U.S. DoI - CGI Federal announced it has been awarded a position on the Foundation Cloud Hosting Services II, FCHS2, 10-year, US$2 billion Indefinite-Delivery, Indefinite-Quantity, IDIQ, contract by the U.S. Department of the Interior, DoI. Under this agreement, CGI offers a comprehensive range of cloud services and solutions in support of critical modernization needs. CGI and its partners bring unique technologies, platforms, and products to critical public missions. CGI leverages its specialized Software-as-a-Service (SaaS) offerings, thought leadership in cloud IT strategies, and cybersecurity consulting to provide meaningful outcomes to the unique needs of our federal clients across agencies.

06:56 EDT Aecom named design partner for Capital Line South Light Rail Transit Extension - AECOM will serve as the design partner subcontracted to Capital Line Design-Build Ltd., a member of the Ledcor Group, to deliver Phase 1 of the City of Edmonton's Capital Line South Light Rail Transit Extension project. Located in Alberta, Canada, the project includes a 4.5-kilometer light rail extension from Century Park to north of Ellerslie Road, two new stations and a light rail vehicle storage and maintenance facility. As a design lead on the Capital Line Design-Build Ltd. team, AECOM will be responsible for infrastructure and systems design. The new line will be built along the west side of 111 Street with an underpass at 23 Avenue, new bridges crossing Blackmud Creek and Anthony Henday Drive and new stations at Twin Brooks and Heritage Valley North. This project will also include a new operations and maintenance facility, with a separate contractor delivering a new fleet of light rail vehicles.

06:51 EDT BWX Technologies announces Hurricane Helene relief - BWX Technologies announced a $100,000 donation to the Unicoi County United Way to support the recovery efforts underway in the Erwin, Tennessee community. This contribution will directly support emergency response teams on the ground, helping to provide essential supplies, medical aid, shelter and long-term recovery services to those affected by this devastating event.

06:36 EDT KalVista reports inducement grants under Nasdaq listing rule - KalVista Pharmaceuticals announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of KalVista common stock on October 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.39 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

06:35 EDT Genenta Science secures approval for trial for metastatic Renal Cell Cancer - Genenta Science announced that the Agenzia Italiana del Farmaco has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer, marking a significant expansion of the potential applications for Genenta's flagship product, Temferon. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency. Genenta's ongoing TEM-GBM development program is progressing having completed a Phase 1 dose-ranging trial that confirmed the absence of dose-limiting toxicities across 24 patients. Temferon-derived cells remained detectable in the peripheral blood for over two years post-infusion. The treatment has been associated with a median survival of 16.8 months, showing a 25% increase in the 2 years overall survival, setting the stage for our decision to advance to Phase 2 of the study. Metastatic disease is evident in 25% of newly diagnosed patients with mRCC. The newly approved mRCC trial, expected to commence in Q4 2024, targets a high-risk patient population whose median overall survival is currently less than 2 years after multiple lines of therapy. IFNalpha, the therapeutic payload delivered by Temferon, has demonstrated benefits across a range of solid tumors, including those involving the urinary tract. This trial aims to leverage similar immune response mechanisms against renal cell cancer.

06:34 EDT Vera Therapeutics to report results from ORIGIN Phase 2b clinical trial - Vera Therapeutics announced that long-term results from the ORIGIN Phase 2b clinical trial of atacicept for the treatment of IgAN will be delivered in a late-breaking oral presentation, and two informational posters will describe the ORIGIN Phase 3 and ORIGIN Extend trials, at the American Society of Nephrology, or ASN, Kidney Week 2024 in San Diego, California, from October 23 to 27. "Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN" will be presented by Jonathan Barratt, The Mayer Professor of Renal Medicine, University of Leicester. "ORIGIN 3: A Global Randomized, Controlled, Phase 3 Study of Atacicept in IgAN" will be presented by Richard Lafayette, Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center. "ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN" will presented by Richard Lafayette, Professor of Medicine, Nephrology and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center.

06:17 EDT YY Group launches advanced workforce solutions in the UK - YY Group Holding announced its expansion into the United Kingdom market. As part of its expansion, YY Circle, the Group's flagship interactive job-matching platform, will now be available to employers and job seekers in the UK's hospitality, retail, and service sectors. These industries, which have been navigating labor shortages and operational challenges, stand to benefit from YY Circle's intelligent workforce management solutions.

06:05 EDT Ensign Group acquires St. Joseph Rehabilitation and Care Center - The Ensign Group, the parent company of the Ensign group of companies announced that it acquired the real estate and operations of St. Joseph Rehabilitation and Care Center, an 83-bed skilled nursing facility; and Skyview Villa Assisted Living, a 20 licensed-bed assisted living facility. Both facilities are located in Norfolk, Nebraska. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign's captive real estate company, and the acquisition is effective as of October 1. This acquisition is effective as of October 1 and brings Ensign's growing portfolio to 324 healthcare operations.

06:03 EDT Redwire provides critical onboard computer system for ESA's Hera misssion - Redwire is providing a critical onboard computer system for the European Space Agency's Hera mission, Europe's inaugural flagship planetary defense mission. Hera is the European-led companion mission to NASA's Double Asteroid Redirection Test, which successfully impacted the binary asteroid system Didymos in September 2022 with Redwire power and navigation technology onboard. The Hera mission will provide a detailed survey of DART's impact site.

05:22 EDT Vail Resorts enters pact to develop West Lionshead into a fourth base village - The Town of Vail, Vail Resorts, and East West Partners announced a partnership to develop the West Lionshead area into a fourth base village at Vail Mountain. The new base village, planned in the location formerly designated for the Ever Vail project is anticipated to feature access to the resort's 5,317 acres of terrain, plus new lodging, restaurants, boutiques, and skier services, as well as community benefits such as workforce housing, public spaces, transit, and parking. The Vail Town Council voted unanimous in favor of the partnership and creating a new master plan for the West Lionshead base village development. The Town will partner with Vail Resorts and East West Partners on the community process to create a new vision and the master plan for the West Lionshead area. The partnership to develop the West Lionshead base village includes incremental workforce housing. As a result, Vail Resorts will dismiss its appeal of the Town of Vail's condemnation of the company's East Vail property that was planned for Vail Resorts' incremental affordable workforce housing project. East West Partners in collaboration with the Town and Vail Resorts will drive community engagement and the design of West Lionshead. After a master plan is completed, East West Partners and Vail Resorts will then pursue the entitlement process for the West Lionshead base village. The development of the West Lionshead base village will undergo a community engagement process starting this fall that will include open houses where community members can offer input on the initiative's vision, design, and planning. The initiative is subject to all applicable entitlement and approval processes.

05:08 EDT AerCap signs lease agreements with Azerbaijan Airlines - AerCap announced that it has signed lease agreements with Azerbaijan Airlines, or AZAL, for six new Airbus CFM LEAP powered aircraft, including three A320neos and three A321neos which are scheduled to deliver in 2026. The lease agreements were signed by Samir Rzayev, president of Azerbaijan Airlines CJSC, and Peter Anderson, chief commercial officer of AerCap.